Search Results - "Berk, Greg"

Abstract CT201: Early report of a phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19 (NCT04365101) by Casper, Corey, Groysman, Leonid, Malhotra, Vinay, Whitman, Eric, Herb, Stacy, Rave, Erica, Lew, Alan, Goman, Cristina, Sagawa, Zachary, Thakar, Monica, Lacasse, Victoria, Daly, Cherie, He, Shuyang, Kang, Lin, Koppisetti, Sharmila, Mahlakõiv, Tanel, Osokoya, Sunday, van der Touw, William, Zhu, Junhong, Berk, Greg, Zhang, Xiaokui, Pecora, Andrew, Hariri, Robert

“…Background CYNK-001 is a cryopreserved, allogeneic, off-the-shelf natural killer (NK) cell investigational product derived from placental CD34+ cells. CYNK-001…”
Get full text

Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial by Li, Bob T., Li, Tianhong, Johnson, Melissa Lynne, Waqar, Saiama Naheed, Zhu, Viola Weijia, Ou, Sai-Hong Ignatius, Lin, Jessica Jiyeong, Wang, Ding, Shapiro, Geoffrey, Wang, Judy Sing-Zan, Liu, Dazhi, Ye, Yuqing, Kosar, Hana, Hee, Angela, Berk, Greg, Zhang, Sean, Wang, Junsheng, Patel, Manish R.

“…Abstract only 3510 Background: Pyrotinib is a potent, irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the erythroblastic…”
Get full text

Abstract 3435: GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas by Khaw, Melissa, Davis, Zachary, Zorko, Nicholas, Berk, Greg, Choy, Gavin, MacMillan, Margaret, Felices, Martin, Miller, Jeffrey S.

“…Worldwide, Head and Neck Squamous Cell Carcinomas (HNSCC) account for about 900,000 cases and 400,000 deaths. In some settings, like Fanconi anemia (FA),…”
Get full text

Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies by Infante, Jeffrey R., Tabernero, Josep, Burris, Howard A., Macarulla, Teresa, Martin, Michael, Liu, Yi, Jessen, Katti, Koczon, Ethel, Rommel, Christian, Klein, Pam M., Berk, Greg I., Bui, Lynne A., Gordon, Michael S.

“…Background: INK128 is an orally bioavailable potent and selective ATP site kinase inhibitor of mammalian target of rapamycin (mTOR) complexes TORC1 and TORC2…”
Get full text

Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies by Tabernero, Josep, Cervantes, Andres, Gordon, Michael S., Chiorean, Elena G., Burris, Howard A., Macarulla, Teresa, Perez-Fidalgo, Alejandro, Martin, Michael, Jessen, Katti, Liu, Yi, Le, Trinh, Rommel, Christian, Berk, Greg I., Bui, Lynne A., Infante, Jeffrey R.

“…Background: INK128 is an orally bioavailable potent and selective ATP site kinase inhibitor of mammalian target of rapamycin (mTOR) complexes TORC1 and TORC2…”
Get full text

IPdR: a novel oral radiosensitizer by Saif, Muhammad Wasif, Berk, Greg, Cheng, Yung-Chi, Kinsella, Timothy James

“…IPdR (5-iodo-2-pyrimidinone-2'-deoxyribose) is a novel orally available, halogenated thymidine (TdR) analog and is a potential radiosensitizer for use in human…”
Get more information

A Phase II Double-Blind Randomized Study of the Simultaneous Administration of Recombinant Human Interleukin-6 and Recombinant Human Granulocyte Colony-Stimulating Factor Following Paclitaxel and Carboplatin Chemotherapy in Patients with Advanced Epithelial Ovarian Cancer by Hochster, Howard, Speyer, James L., Mandeli, John P., Runowicz, Carolyn, Wadler, Scott, Berk, Greg, Wallach, Robert, Holland, James F.

“…Purpose.Recombinant human interleukin-6 (rhuIL-6) is a glycosylated cytokine with hematopoietic stimulatory effects. In particular, preclinical studies suggest…”
Get full text